GlassScriptPhysician profile
Syed Parvez Ashraf
NPI 1760431860
$5,317.82
in general payments reported to CMS, 2019-2025
33 companies · $1,074 in 2025
The $1,074 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $580 · 2021: $383 · 2022: $676 · 2023: $563 · 2024: $654 · 2025: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,258 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,258.49 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $687.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $618.21 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $509.70 | 2019-2025 | Linzess, Viberzi |
| Novartis Pharmaceuticals Corporation | $414.81 | 2019-2025 | |
| Amgen INC. | $342.09 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $340.07 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $284.40 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $231.22 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.75 | 2019-2025 | Jardiance, Ofev |
| E.R. Squibb & Sons, L.L.C. | $192.90 | 2019-2023 | Eliquis |
| Otsuka America Pharmaceutical, INC. | $178.03 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $168.96 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $160.14 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $157.86 | 2019-2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $141.05 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.76 | 2022-2025 | Xifaxan |
| Amarin Pharma, INC. | $65.71 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $53.58 | 2021-2023 | |
| Allergan, INC. | $53.30 | 2019 | |
| Abbott Laboratories | $42.84 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $41.38 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $37.57 | 2025 | Vowst |
| Avanir Pharmaceuticals, INC. | $36.64 | 2020-2021 | |
| Axsome Therapeutics, INC. | $33.59 | 2025 | Auvelity |
| Eisai INC. | $25.00 | 2021 | |
| Scilex Pharmaceuticals INC. | $22.97 | 2019 | |
| Corcept Therapeutics | $20.29 | 2025 | Korlym |
| Echosens North America, INC. | $17.99 | 2025 | Fibroscan |
| Sanofi Pasteur INC. | $16.99 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.63 | 2022 | |
| Esperion Therapeutics, INC. | $14.78 | 2023 | Nexletol |
| Philips North America LLC | $14.36 | 2025 | Extended Holter |
| Horizon Therapeutics Plc | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ashraf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.